BIOSPAIN expandingMatured, diversified and willing to expand – this is how the Spanish biotech sector presented itself during BIOSPAIN 2018 in Seville. Andalusia has launched the first bioeconomy policy strategy in S … more ➔
Minoryx bags €21.3m Series B financingBarcelona-based Minoryx Therapeutics announced during BIOSPAIN 2018 it has raised another €21.3m in a Series B financing bringing its assets to a total of €50M. more ➔
PD-1+ T cells trigger pulmonary fibrosisA team of researchers from the US and the UK have found that CD4-positive T cells harboring the PD-1 immune checkpoint protein can promote excessive connective tissue formation in lung cells.&n … more ➔
Roches Tecentriq prolongs OS in SCLCCancer immunotherapy has been heralded as paradigm change in cancer treatment. Now, Roche’s US arm Genentech announced that the companys anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) improved … more ➔
CRISPR-gene drive safely kills mosquitos A new gene drive can cause the complete collapse of caged malaria-carrying mosquito populations, researchers from Imperial College report in Nature Biotechnology. more ➔
CHMP with new Chair – 13 meds recomm...The CHMP elected Harald Enzmann as its new Chair on Friday, and recommended thirteen medicines for approval, three thereof orphan medicines. more ➔
European biotech companies enter IPO prep...European stock exchange operator Euronext kicked off its fourth annual capital markets training programme for non-listed companies – this time also including companies from Germany, Italy, Spain, and … more ➔
Novo Nordisk reveals details about its R&#...Novo Nordisk A/S (NOVOB:DC) said it plans to restructure its entire Research & Development (R&D) organization. Consequently, the company will lay off 400 employees from R&D roles in Denmark … more ➔
Pharming receives complete response letter...The FDA has requested additional clincal data demonstrating that Pharming Group’s recombinant C1 esterase blocker Ruconest can prevent hereditary angioedema attacks (HAE). more ➔
CRISPR Therapeutics and Viacyte launch dia...CRISPR Therapeutics AG announced a development partnership with ViaCyte Inc to develop genome-edited pancreatic islet cells, which do not require immunosuppression, to treat diabetes. more ➔
